Cargando…

A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy

Background: Bloodstream infection (BSI) is a common and serious complication after patients with hematologic malignancies (HM) receiving chemotherapy. This study examined real-world data seeking to characterize HM BSI and identify risk factors for BSI emergence and mortality. Methods: We retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shaozhen, Lin, Kangni, Li, Qian, Luo, Xiaofeng, Xiao, Min, Chen, Minmin, Zhu, Haojie, Chen, Yongquan, Wu, Xueqiong, Zeng, Yanling, Zhang, Yuxin, Ally, Issa Hajji, Xu, Jingjing, Ren, Jinhua, Chen, Zhizhe, Hu, Jianda, Yang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364636/
https://www.ncbi.nlm.nih.gov/pubmed/34405012
http://dx.doi.org/10.7150/jca.50802
_version_ 1783738555497971712
author Chen, Shaozhen
Lin, Kangni
Li, Qian
Luo, Xiaofeng
Xiao, Min
Chen, Minmin
Zhu, Haojie
Chen, Yongquan
Wu, Xueqiong
Zeng, Yanling
Zhang, Yuxin
Ally, Issa Hajji
Xu, Jingjing
Ren, Jinhua
Chen, Zhizhe
Hu, Jianda
Yang, Ting
author_facet Chen, Shaozhen
Lin, Kangni
Li, Qian
Luo, Xiaofeng
Xiao, Min
Chen, Minmin
Zhu, Haojie
Chen, Yongquan
Wu, Xueqiong
Zeng, Yanling
Zhang, Yuxin
Ally, Issa Hajji
Xu, Jingjing
Ren, Jinhua
Chen, Zhizhe
Hu, Jianda
Yang, Ting
author_sort Chen, Shaozhen
collection PubMed
description Background: Bloodstream infection (BSI) is a common and serious complication after patients with hematologic malignancies (HM) receiving chemotherapy. This study examined real-world data seeking to characterize HM BSI and identify risk factors for BSI emergence and mortality. Methods: We retrospectively analyzed the pathogenic epidemiology, antibiotic resistance, and BSI risk factors in a single-center cohort including 3014 consecutive patients with HM receiving chemotherapy between 2013 and 2016. Results of the pathogenic epidemiology were validated via comparison to available reported data. Results: We found that 725 patients (24.1%) had BSIs. Gram-negative (G-) bacteria represented 64.7% of the 744 isolated pathogenic strains, while Gram-positive (G+) bacteria and fungi accounted for 27.7% and 7.7% of the BSIs, respectively. The most common isolates were Klebsiella pneumoniae (19.2%), and 95.1% of the multidrug-resistant strains (MDR) were extended-spectrum beta-lactamase producing strains. G- bacteria were the main microflora responsible for BSI in our cohort of Chinese HM patients compared to studies in developed countries or in neutropenic children with HM or solid tumors. Multivariate analysis revealed that male sex, age ≥ 45 and < 65 yr, hospital length of stay ≥ 9d, neutropenia ≥ 7d before cultures, ≥ 2 antibiotics, and infections (gastrointestinal, perirectal, or urinary tract) independently predicted BSI emergence. Furthermore, age ≥ 65 yr, neutropenia ≥ 7d before blood cultures, no HM remission, lower white blood cell count, ≥ 3 antibiotics, respiratory infections, and Acinetobacter baumannii and Stenotrophomonas maltophilia BSI were independent predictors of 30-day mortality. Conclusions: G- bacteria were the predominant microflora during the study period and antibiotic resistance levels of the pathogens detected were high, especially for MDR strains. The mortality of BSI patients was high in this large cohort. Close attention should be paid to the risk factors identified here to facilitate timely and effective clinical management of such patients.
format Online
Article
Text
id pubmed-8364636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-83646362021-08-16 A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy Chen, Shaozhen Lin, Kangni Li, Qian Luo, Xiaofeng Xiao, Min Chen, Minmin Zhu, Haojie Chen, Yongquan Wu, Xueqiong Zeng, Yanling Zhang, Yuxin Ally, Issa Hajji Xu, Jingjing Ren, Jinhua Chen, Zhizhe Hu, Jianda Yang, Ting J Cancer Research Paper Background: Bloodstream infection (BSI) is a common and serious complication after patients with hematologic malignancies (HM) receiving chemotherapy. This study examined real-world data seeking to characterize HM BSI and identify risk factors for BSI emergence and mortality. Methods: We retrospectively analyzed the pathogenic epidemiology, antibiotic resistance, and BSI risk factors in a single-center cohort including 3014 consecutive patients with HM receiving chemotherapy between 2013 and 2016. Results of the pathogenic epidemiology were validated via comparison to available reported data. Results: We found that 725 patients (24.1%) had BSIs. Gram-negative (G-) bacteria represented 64.7% of the 744 isolated pathogenic strains, while Gram-positive (G+) bacteria and fungi accounted for 27.7% and 7.7% of the BSIs, respectively. The most common isolates were Klebsiella pneumoniae (19.2%), and 95.1% of the multidrug-resistant strains (MDR) were extended-spectrum beta-lactamase producing strains. G- bacteria were the main microflora responsible for BSI in our cohort of Chinese HM patients compared to studies in developed countries or in neutropenic children with HM or solid tumors. Multivariate analysis revealed that male sex, age ≥ 45 and < 65 yr, hospital length of stay ≥ 9d, neutropenia ≥ 7d before cultures, ≥ 2 antibiotics, and infections (gastrointestinal, perirectal, or urinary tract) independently predicted BSI emergence. Furthermore, age ≥ 65 yr, neutropenia ≥ 7d before blood cultures, no HM remission, lower white blood cell count, ≥ 3 antibiotics, respiratory infections, and Acinetobacter baumannii and Stenotrophomonas maltophilia BSI were independent predictors of 30-day mortality. Conclusions: G- bacteria were the predominant microflora during the study period and antibiotic resistance levels of the pathogens detected were high, especially for MDR strains. The mortality of BSI patients was high in this large cohort. Close attention should be paid to the risk factors identified here to facilitate timely and effective clinical management of such patients. Ivyspring International Publisher 2021-07-25 /pmc/articles/PMC8364636/ /pubmed/34405012 http://dx.doi.org/10.7150/jca.50802 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Chen, Shaozhen
Lin, Kangni
Li, Qian
Luo, Xiaofeng
Xiao, Min
Chen, Minmin
Zhu, Haojie
Chen, Yongquan
Wu, Xueqiong
Zeng, Yanling
Zhang, Yuxin
Ally, Issa Hajji
Xu, Jingjing
Ren, Jinhua
Chen, Zhizhe
Hu, Jianda
Yang, Ting
A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title_full A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title_fullStr A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title_full_unstemmed A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title_short A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
title_sort practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364636/
https://www.ncbi.nlm.nih.gov/pubmed/34405012
http://dx.doi.org/10.7150/jca.50802
work_keys_str_mv AT chenshaozhen apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT linkangni apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT liqian apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT luoxiaofeng apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT xiaomin apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenminmin apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zhuhaojie apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenyongquan apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT wuxueqiong apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zengyanling apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zhangyuxin apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT allyissahajji apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT xujingjing apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT renjinhua apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenzhizhe apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT hujianda apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT yangting apracticalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenshaozhen practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT linkangni practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT liqian practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT luoxiaofeng practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT xiaomin practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenminmin practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zhuhaojie practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenyongquan practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT wuxueqiong practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zengyanling practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT zhangyuxin practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT allyissahajji practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT xujingjing practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT renjinhua practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT chenzhizhe practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT hujianda practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy
AT yangting practicalupdateontheepidemiologyandriskfactorsfortheemergenceandmortalityofbloodstreaminfectionsfromrealworlddataof3014hematologicalmalignancypatientsreceivingchemotherapy